Drug Trial Radar · NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
Jul 16, 2026
Primary completion
May 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- VM Discovery, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed. VMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver/HCC tumor models and preclinical toxicology and pharmacology studies support this study.
Conditions
- Hepatocellular Carcinoma (HCC)
- Metastatic Uveal Melanoma
- Renal Cell Carcinoma (RCC)
- Nonsmall Cell Lung Cancer
- Colorectal Cancer (CRC)
Interventions
VMD-102Drug
A small organic molecule oral drug in the tablet form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of treatment-emergent adverse events (TEAE) (Phase 1)Time frame: First cycle (21 days per cycle)
- To determine the recommended Phase 2 dose (RP2D) for VMD-102 (Phase 1)Time frame: First cycle (21 days per cycle)
- Progression-Free Survival (PFS) (Phase 2)Time frame: Up to 18 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute (#600)
Scottsdale, Arizona · Recruiting
The Angeles Clinic and Research Institute (#601)
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.